NICE accepts golimumab in rheumatoid arthritis

NICE has recommended golimumab (Simponi), in combination with methotrexate, as another option for the treatment of active rheumatoid arthritis. Like other tumour necrosis factor (TNF) inhibitors, it can be considered for use in patients with:

  • a disease activity score greater than 5.1 on two separate occasions at least 1 month apart, who have undergone trials of two conventional DMARDs, including methotrexate (unless contraindicated), or
  • severe rheumatoid arthritis, who have inadequately responded to other DMARDs, including at least one TNF inhibitor, and for whom rituximab is inappropriate.

NICE approval of golimumab is contingent on the manufacturer supplying the 100mg dose, which should be considered for use in patients >100kg, at the same price as the 50mg dose.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Removed: Xepin.
Use our constantly updated shortages...

Vaping still safer than smoking, say health bosses after report of severe lung injury
Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

GPs should consider online vestibular rehabilitation...

Thiazides better than ACE inhibitors as first-line antihypertensives, large-scale analysis suggests